Top Boston, MA Biotech Companies (274)
Ambit Consulting Services (ACS) is a rapidly-expanding team of professionals dedicated to helping our clients deliver innovative therapies to improve the lives of patients. ACS provides guidance on our clients’ biggest strategic challenges, including corporate, medical and digital strategy and organizational transformation. Our work is informed by our extensive collective experience, but we don’t rely on cookie-cutter templates. In keeping our eye on the big picture, we also don’t lose sight of the “on-the-ground” realities of strategy implementation. As such, we highly value intellectual curiosity among our team – a willingness to continually dig deeper to understand the “why” and “how” of addressing a client challenge. Our work is fast-paced but intellectually invigorating. We support our employees and their career growth, fostering a team of talented, collegial individuals who are continually striving to help our clients succeed.
Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
PharmaLex is a leading provider of specialized services for the pharma, biotech and medtech industries. We guide you from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval/maintenance post-launch activities. Our experts use technology enabled solutions to support you through the entire product lifecycle. We deliver exceptional results - going above and beyond the standard to deliver tailor-made solutions worldwide. The PharmaLex Group now has over 3000 employees, with 68 offices in 32 countries and more than 1000 satisfied clients worldwide.
OpenClinica is transforming healthcare through innovative cloud technology that simplifies running clinical trials. Proven in over 10,000 studies worldwide, the OpenClinica platform is trusted by biopharmaceutical companies, CROs, AROs, and government agencies. Research organizations leverage OpenClinica to capture better clinical data faster with the highest standards for security and regulatory compliance.
Revolutionizing life sciences procurement. AI-powered digital purchasing platform for complete transparency into your supply chain Labviva integrates with your existing purchasing software to provide you with actionable insights to make better decisions. Keep your current suppliers, contract pricing, and your purchasing software and processes. Our digital marketplace offers unparalleled visibility into your procurement process, to empower informed decisions to drive science forward without interruptions to your research
The trillions of microbes that call us home –the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival. Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a group of world renowned experts in immunology and microbiology
AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+.
We are Bicycle Therapeutics, a clinical-stage biopharmaceutical company. We didn’t wait for the next advance against cancer. We created it. Based on groundbreaking work conceived in the laboratory of Sir Greg Winter with the help of Professor Christian Heinis, we are pioneering the development of bicyclic peptides, or Bicycles® – a novel class of versatile, chemically synthesized medicines. Bicycles are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycles represent a unique therapeutic class, combining the pharmacological properties normally associated with a biologic with the manufacturing and pharmacokinetic advantages of a small molecule, yet with no signs of immunogenicity observed to date. Bicycles can be used as Bicycle conjugates to deliver toxin payloads and to precisely target local immune activation within tumors and as Bicycle T-cell modulators, which activate cytotoxic T-cells while circumventing the limitations of antibody and biologic therapies and better enabling combination therapy. Our lead product candidate, BT1718, is a Bicycle toxin conjugate currently being investigated in a Phase I/IIa open label dose escalation and expansion clinical trial sponsored by Cancer Research UK. BT1718 targets Membrane Type 1 Matrix Metalloproteinase (MT1-MMP), also known as MMP-14, which is highly expressed in many solid tumors. Our strategic collaborations are based on the ability of Bicycles to address a wide variety of targets. Through collaborations with AstraZeneca, Oxurion, Innovate UK and the Dementia Discovery Fund, we work with companies that have deep therapeutic expertise outside of oncology to enable us to more efficiently develop novel medicines for patients.
Anodyne Nanotech, Inc. is a preclinical-stage biotech company developing differentiated, transdermal forms of high-value drugs. The company’s macroporous microneedle technology provides the first practical and cost-effective platform, Hero Patch, to deliver clinically meaningful doses of macromolecules such as monoclonal antibodies or small molecules (such as ibuprofen) for fast and sustained delivery. We pride ourselves on providing a painless experience for all of those involved in the production, delivery, and consumption of medicines.
At Nimbus, we design breakthrough medicines. Utilizing our powerful structure-based drug discovery engine, we create potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. With a decade-plus track record of success, we’ve built a world-class team in both computationally driven drug discovery and early clinical development while continuing to move the needle for patients.
We help health & wellness companies find their authentic edge and leverage it for growth. EnticEdge is a boutique consulting firm that brings together value-focused strategy and customer-centered design. We customize effective approaches for our clients to convert new customers and further grow their businesses. Our strategic team has decades of experience helping healthcare and wellness companies redefine their value and create compelling messaging around what differentiates them from the competition. With vast knowledge of the healthcare ecosystem, and wellness space, we advise on redefining company or division strategies around your unique value in the marketplace, building meaningful partnerships, helping align stakeholders, and successfully engaging with new innovations - from new incentive models to new technology integration.
LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere. Through its proprietary, evolutionarily-derived genomic drug discovery platform, LifeMine aims to bring unparalleled speed, predictability and scalability to small molecule drug discovery. LifeMine has discovered, in genomic space, hundreds of potentially high-impact drug candidates relevant to targets across all major disease areas, and has an initial focus on advancing highly impactful precision medicines in oncology and immune modulation. The Company was founded in 2017 by renowned entrepreneur/scientists Gregory Verdine, Ph.D., and Richard Klausner, M.D., and entrepreneur/company-builder WeiQing Zhou.
Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
